Eli Lilly and Company (LLY)

Eli Lilly and Company records an AlphaScore of 68/100 in the Healthcare sector, anchored by a large market capitalization of $1051.15 billion. Essential fundamentals include a high return on equity of 77.78% and a very strong gross margin of 83.04%. A primary strength is its exceptional revenue growth of 44.70% paired with a growth subScore of 98/100. A notable risk is its high trailing price-to-earnings ratio of 39.59 alongside a low safety subScore of 49/100. Evidence is limited to this snapshot date of 2026-10-11.

Written 11/10/2026, 00:23:07 UTC · Snapshot 11/10/2026